Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma: early-phase trial registry
3 of 4 indexed Metastatic Renal Pelvis and Ureter Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma: 4 US clinical trials tracked, 3 recruiting.
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-renal-pelvis-and-ureter-urothelial-carcinoma
OPEN 3 | RECR 75% | LATE 1 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Renal Pelvis and Ureter Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
University of Washington
NCT01050504
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT06764095
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Mayo Clinic
NCT07087860
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT02567409
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Renal Pelvis and Ureter Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Renal Pelvis and Ureter Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Renal Pelvis and Ureter Urothelial Carcinoma page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Renal Pelvis and Ureter Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Metastatic Renal Pelvis and Ureter Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Renal Pelvis and Ureter Urothelial Carcinoma condition card totals 4 registered trials; most-linked intervention Enfortumab Vedotin; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.